Entain (LON:ENT – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat.com reports.
A number of other brokerages also recently issued reports on ENT. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Entain in a report on Wednesday, June 14th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,805 ($23.07) price target on shares of Entain in a report on Friday, June 16th. Finally, Barclays reiterated an “overweight” rating and set a GBX 1,450 ($18.53) target price on shares of Entain in a research report on Tuesday, July 25th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Entain has a consensus rating of “Buy” and an average target price of GBX 1,822.50 ($23.29).
Check Out Our Latest Stock Report on Entain
Entain Trading Down 4.9 %
Insider Transactions at Entain
In related news, insider Rob Wood sold 52,808 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of GBX 1,210 ($15.46), for a total value of £638,976.80 ($816,583.77). Corporate insiders own 0.14% of the company’s stock.
Entain Company Profile
Entain PLC operates as a sports-betting and gaming company. The company provides online betting, casino, poker, and bingo services through mobile and web under the bwin; online and multi-channel betting under the Ladbrokes; street and online betting under the Coral; sports betting, casino, game, and poker under the Sportingbet; and sports betting, poker, and casino games under the Crystalbet brands, as well as Gamebookers, a full-service sportsbook.
Featured Stories
- Five stocks we like better than Entain
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Investing in Coffee: 3 Great Strategies to Consider
- How to Invest in Casino Stocks
- 5 Best Stocks to Buy in a Bear Market
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Entain Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entain and related companies with MarketBeat.com's FREE daily email newsletter.